147 related articles for article (PubMed ID: 7532566)
1. Markers for metastatic adenocarcinoma in serous effusion specimens.
Shield PW; Callan JJ; Devine PL
Diagn Cytopathol; 1994; 11(3):237-45. PubMed ID: 7532566
[TBL] [Abstract][Full Text] [Related]
2. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
3. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
4. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
Chen CJ; Chang SC; Tseng HH
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
[TBL] [Abstract][Full Text] [Related]
5. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
6. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
7. Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA.
Stoop JA; Hendriks JG; Berends D
Cytopathology; 1992; 3(5):297-302. PubMed ID: 1288655
[TBL] [Abstract][Full Text] [Related]
8. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
10. Ber-EP4 staining in effusion cytology: A potential source of false positives.
Díaz Del Arco C; Saiz-Pardo Sanz M; Ortega Medina L; Fernández Aceñero MJ
Rev Esp Patol; 2021; 54(2):114-122. PubMed ID: 33726887
[TBL] [Abstract][Full Text] [Related]
11. Distinction between cells in serous effusions using a panel of antibodies.
Lauritzen AF
Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518
[TBL] [Abstract][Full Text] [Related]
12. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
13. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
14. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
15. Immunofluorescent staining of metastatic carcinoma cells in serious fluid with carcinoembryonic antibody, epithelial membrane antibody, AUA-1 and Ber-EP4.
Illingworth AL; Young JA; Johnson GD
Cytopathology; 1994 Oct; 5(5):270-81. PubMed ID: 7819512
[TBL] [Abstract][Full Text] [Related]
16. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
De Angelis M; Buley ID; Heryet A; Gray W
Cytopathology; 1992; 3(2):111-7. PubMed ID: 1617160
[TBL] [Abstract][Full Text] [Related]
18. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
19. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry.
Queiroz C; Barral-Netto M; Bacchi CE
Acta Cytol; 2001; 45(1):18-22. PubMed ID: 11213499
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions.
Lauritzen AF
APMIS; 1989 Aug; 97(8):761-6. PubMed ID: 2765278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
